Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Phosphorylation of PDE4A5 by MAPKAPK2 attenuates fibrin degradation via p75 signalling.

Houslay KF, Fertig BA, Christian F, Tibbo AJ, Ling J, Findlay JE, Houslay MD, Baillie GS.

J Biochem. 2019 Jul 1;166(1):97-106. doi: 10.1093/jb/mvz016.

2.

Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation.

MacKenzie KF, Wallace DA, Hill EV, Anthony DF, Henderson DJ, Houslay DM, Arthur JS, Baillie GS, Houslay MD.

Biochem J. 2011 May 1;435(3):755-69. doi: 10.1042/BJ20101184.

PMID:
21323643
3.

Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.

Havekes R, Park AJ, Tolentino RE, Bruinenberg VM, Tudor JC, Lee Y, Hansen RT, Guercio LA, Linton E, Neves-Zaph SR, Meerlo P, Baillie GS, Houslay MD, Abel T.

J Neurosci. 2016 Aug 24;36(34):8936-46. doi: 10.1523/JNEUROSCI.0248-16.2016.

4.

Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners.

Houslay KF, Christian F, MacLeod R, Adams DR, Houslay MD, Baillie GS.

Biochem J. 2017 Feb 15;474(4):597-609. doi: 10.1042/BCJ20160849. Epub 2016 Dec 19.

5.

Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression.

Sheppard CL, Lee LC, Hill EV, Henderson DJ, Anthony DF, Houslay DM, Yalla KC, Cairns LS, Dunlop AJ, Baillie GS, Huston E, Houslay MD.

Cell Signal. 2014 Sep;26(9):1958-74. doi: 10.1016/j.cellsig.2014.04.023. Epub 2014 May 9.

PMID:
24815749
6.
7.

Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Zhao CY, Greenstein JL, Winslow RL.

J Mol Cell Cardiol. 2015 Nov;88:29-38. doi: 10.1016/j.yjmcc.2015.09.011. Epub 2015 Sep 23.

8.

Regulation of cAMP by the p75 neurotrophin receptor: insight into drug design of selective phosphodiesterase inhibitors.

Sachs BD, Akassoglou K.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1273-7. Review.

PMID:
17956328
9.

Type I interferons up-regulate the expression and signalling of p75 NTR/TrkA receptor complex in differentiated human SH-SY5Y neuroblastoma cells.

Dedoni S, Olianas MC, Ingianni A, Onali P.

Neuropharmacology. 2014 Apr;79:321-34. doi: 10.1016/j.neuropharm.2013.12.002. Epub 2013 Dec 11.

PMID:
24333329
10.

Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2.

Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, Houslay MD.

J Biol Chem. 2003 Aug 29;278(35):33351-63. Epub 2003 Jun 16.

11.

AKAP3 selectively binds PDE4A isoforms in bovine spermatozoa.

Bajpai M, Fiedler SE, Huang Z, Vijayaraghavan S, Olson GE, Livera G, Conti M, Carr DW.

Biol Reprod. 2006 Jan;74(1):109-18. Epub 2005 Sep 21.

12.

Glioma invasion mediated by the p75 neurotrophin receptor (p75(NTR)/CD271) requires regulated interaction with PDLIM1.

Ahn BY, Saldanha-Gama RF, Rahn JJ, Hao X, Zhang J, Dang NH, Alshehri M, Robbins SM, Senger DL.

Oncogene. 2016 Mar 17;35(11):1411-22. doi: 10.1038/onc.2015.199. Epub 2015 Jun 29.

13.

p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway.

Sachs BD, Baillie GS, McCall JR, Passino MA, Schachtrup C, Wallace DA, Dunlop AJ, MacKenzie KF, Klussmann E, Lynch MJ, Sikorski SL, Nuriel T, Tsigelny I, Zhang J, Houslay MD, Chao MV, Akassoglou K.

J Cell Biol. 2007 Jun 18;177(6):1119-32.

14.

Genetic dissection of neurotrophin signaling through the p75 neurotrophin receptor.

Charalampopoulos I, Vicario A, Pediaditakis I, Gravanis A, Simi A, Ibáñez CF.

Cell Rep. 2012 Dec 27;2(6):1563-70. doi: 10.1016/j.celrep.2012.11.009. Epub 2012 Dec 20.

15.

p75NTR-mediated signaling promotes the survival of myoblasts and influences muscle strength.

Reddypalli S, Roll K, Lee HK, Lundell M, Barea-Rodriguez E, Wheeler EF.

J Cell Physiol. 2005 Sep;204(3):819-29.

PMID:
15754321
16.

cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.

Bolger GB, Bizzi MF, Pinheiro SV, Trivellin G, Smoot L, Accavitti MA, Korbonits M, Ribeiro-Oliveira A Jr.

Endocr Relat Cancer. 2016 May;23(5):419-31. doi: 10.1530/ERC-15-0205.

17.

An intracellular domain fragment of the p75 neurotrophin receptor (p75(NTR)) enhances tropomyosin receptor kinase A (TrkA) receptor function.

Matusica D, Skeldal S, Sykes AM, Palstra N, Sharma A, Coulson EJ.

J Biol Chem. 2013 Apr 19;288(16):11144-54. doi: 10.1074/jbc.M112.436469. Epub 2013 Mar 7.

18.

Mapping of the interaction site between sortilin and the p75 neurotrophin receptor reveals a regulatory role for the sortilin intracellular domain in p75 neurotrophin receptor shedding and apoptosis.

Skeldal S, Sykes AM, Glerup S, Matusica D, Palstra N, Autio H, Boskovic Z, Madsen P, Castrén E, Nykjaer A, Coulson EJ.

J Biol Chem. 2012 Dec 21;287(52):43798-809. doi: 10.1074/jbc.M112.374710. Epub 2012 Oct 26.

19.

Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants.

Hernández-Ramírez LC, Trivellin G, Stratakis CA.

Horm Metab Res. 2017 Apr;49(4):286-295. doi: 10.1055/s-0043-104700. Epub 2017 Apr 20. Review.

PMID:
28427099
20.

Relative expression of the p75 neurotrophin receptor, tyrosine receptor kinase A, and insulin receptor in SH-SY5Y neuroblastoma cells and hippocampi from Alzheimer's disease patients.

Ito S, Ménard M, Atkinson T, Brown L, Whitfield J, Chakravarthy B.

Neurochem Int. 2016 Dec;101:22-29. doi: 10.1016/j.neuint.2016.09.015. Epub 2016 Sep 29.

PMID:
27693452

Supplemental Content

Support Center